Key Highlights

  • Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24.
  • BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing peptide uncertainty.
  • Last week's 6% pullback reflected softer-than-expected retention for oral GLP-1 members and ongoing gross margin compression concerns, even as full-year guidance was raised to $2.8-$3 billion.

Hims & Hers Health (NYSE: HIMS) shares are trading flat flat near $34.47 today, moving in line with the broader healthcare sector, as investors weigh a mix of company-specific catalysts and broader macro developments.

Investors are balancing a mixed analyst outlook ahead of a pivotal FDA advisory committee meeting on peptides scheduled for July 23-24. BofA recently raised its price target to $37 while Canaccord sits at $40, but Truist maintained a Hold with a $23 target citing peptide uncertainty.

Last week's 6% pullback reflected softer-than-expected retention for oral GLP-1 members and ongoing gross margin compression concerns, even as full-year guidance was raised to $2.8-$3 billion.

Today's move is also unfolding against a broader risk backdrop, as renewed U.S.-Iran hostilities have sent oil prices sharply higher and injected a risk-off tone across equity markets. The healthcare sector, tracked by the XLV ETF, is itself navigating this volatile macro environment, with investors weighing geopolitical headline risk alongside company-specific fundamentals heading into a pivotal earnings season.

Looking ahead, investors will be watching how Hims & Hers Health's next earnings report and any further analyst commentary shape the stock's trajectory, particularly as markets continue to digest both company-specific catalysts and the broader macro backdrop of geopolitical tension and shifting interest rate expectations.